COMPANY PROFILE // THE 014 REPORT
Theravance Biopharma, Inc.
Assembled from 2 government sources in 0.2 s
FLAGS · DISCLOSURE · SUMMARY
Missing or hidden
- Amber8-K Item 3.01 filed: notice of delisting, of a failed continued-listing rule, or of a transfer of listing on 2026-09-23 (last 24 months).
✓ SEC filings✗ LEI✗ SAM registration✗ IRS return✗ State registration✗ Website✗ Lobbying registration
No LEI, no SAM registration, no IRS return, no state registration, no website, no lobbying registration on record.
Theravance Biopharma, Inc. is an SEC-registered operating company in pharmaceutical preparations, incorporated in CA, based in George Town, Grand Cayman, CA.[source] It reported revenue of $107.5 million for the fiscal year ended 2025-12-31.[source] It has filed 94 documents with the SEC in the last 12 months; the latest is a SCHEDULE 13G/A, filed 2026-11-16.[source] Its largest institutional holders on 13F filings are Madison Avenue Partners, LP, Weiss Asset Management LP, BlackRock, Inc. (as of 2026-06-30).[source] Seraphix flags 1 item from these records: 8-K Item 3.01 filed.[source]
- red0
- amber1
- info0
- Madison Avenue Partners, LP$156.6M
- Weiss Asset Management LP$126.8M
- BlackRock, Inc.$77.6M
- Newtyn Management, LLC$58.4M
- Irenic Capital Management LP$46.9M
- VANGUARD CAPITAL MANAGEMENT LLC$30.1M
- STATE STREET CORP$22.6M
- TWO SIGMA INVESTMENTS, LP$20.8M
RECORD · WEB
Ask about this entity
Answers come from this 014 first; every line is marked RECORD (our record, linked) or WEB (a web page, credited and linked).
EVERY LIST AND SOURCE · DATED
Checked and clear
26 lists and sources checked: 26 CLEAR, 0 POSSIBLE MATCH, 0 MATCH. Screening lists are checked when this 014 is built; the enforcement and registry sources at the last company-engine build. Each date is the date of that check.
EVERY IDENTIFIER · LINKED
ID crosswalk
| Identifier | Value | Record |
|---|---|---|
| SEC CIK | 0001583107 | source |
| EIN | 00-0000000 | source |
| Business address (SEC) | UGLAND HOUSE, SOUTH CHURCH STREET, GEORGE TOWN, GRAND CAYMAN, CA, KY1-1104 | source |
Does not exist in the records we hold: LEI, UEI, NY DOS ID, FDIC certificate.
EACH FEEDS WATCH
Dates coming up
- 2027-03-31 · in 129 days · Next 10-K due (period ended 2026-12-31; Non-accelerated filer<br>Smaller reporting company) (computed from the fiscal year end and filer status)
- 2027-05-15 · in 174 days · Next 10-Q due (period ended 2027-03-31; Non-accelerated filer<br>Smaller reporting company) (computed from the fiscal year end and filer status)
PEERS BY SIC CODE
Industry context
SIC 2834 (pharmaceutical preparations): 568 companies in our records share this code.
Peers, each with its 014
- PFIZER INC · 124 SEC filings in 12 months · $25.74B federal (possible match)
- Merck & Co., Inc. · 150 SEC filings in 12 months · $13.51B federal (possible match)
- ABBOTT LABORATORIES · 118 SEC filings in 12 months · 1 flag · $2.64B federal (possible match)
- ASTRAZENECA PLC · 140 SEC filings in 12 months · $602.8M federal (possible match)
- TEVA PHARMACEUTICAL INDUSTRIES LTD · 168 SEC filings in 12 months · $77.6M federal (possible match)
- NOVARTIS AG · 34 SEC filings in 12 months · $41.9M federal (possible match)
- Spero Therapeutics, Inc. · 41 SEC filings in 12 months · 4 flags · $39.5M federal (possible match)
- Grifols SA · 18 SEC filings in 12 months · $22.5M federal (possible match)
- SCYNEXIS INC · 54 SEC filings in 12 months · 3 flags · $18.5M federal (possible match)
- Ensysce Biosciences, Inc. · 45 SEC filings in 12 months · 3 flags · $15.1M federal (possible match)
- UNITED THERAPEUTICS Corp · 454 SEC filings in 12 months · 2 flags · $6.8M federal (possible match)
- Zoetis Inc. · 144 SEC filings in 12 months · 1 flag · $6.7M federal (possible match)
EVERY SOURCE · NEWEST FIRST
One timeline
- 2026-10-05 filing 15-12G · SEC EDGAR
- 2026-09-25 filing SCHEDULE 13D/A · SEC EDGAR
- 2026-09-24 filing S-8 POS · SEC EDGAR
- 2026-09-24 filing S-8 POS · SEC EDGAR
- 2026-09-24 filing S-8 POS · SEC EDGAR
- 2026-09-24 filing S-8 POS · SEC EDGAR
- 2026-09-24 filing S-8 POS · SEC EDGAR
- 2026-09-24 filing S-8 POS · SEC EDGAR
- 2026-09-24 filing S-8 POS · SEC EDGAR
- 2026-09-24 filing S-8 POS · SEC EDGAR
- 2026-09-24 filing S-8 POS · SEC EDGAR
- 2026-09-24 filing S-8 POS · SEC EDGAR
- 2026-09-23 filing 25-NSE · SEC EDGAR
- 2026-09-23 officer change 8-K items 1.01,2.01,3.01,3.03,5.01,5.02,5.03,8.01,9.01 · SEC EDGAR
- 2026-09-18 filing 8-K items 5.07 · SEC EDGAR
- 2026-09-15 filing 144 · SEC EDGAR
- 2026-09-10 filing 8-K items 8.01 · SEC EDGAR
- 2026-08-25 filing DEFA14A · SEC EDGAR
- 2026-08-25 filing 8-K items 8.01,9.01 · SEC EDGAR
- 2026-08-21 filing DEFM14A · SEC EDGAR
- 2026-08-11 filing PREM14A · SEC EDGAR
- 2026-08-11 filing Quarterly report (10-Q) · SEC EDGAR
- 2026-08-10 filing 8-K items 2.02,9.01 · SEC EDGAR
- 2026-06-29 filing DEFA14A · SEC EDGAR
- 2026-06-29 filing 8-K items 1.01,7.01,8.01,9.01 · SEC EDGAR
- 2026-06-23 officer change 8-K items 5.02 · SEC EDGAR
- 2026-06-15 filing 144 · SEC EDGAR
- 2026-06-12 filing 8-K items 5.07 · SEC EDGAR
- 2026-05-07 filing Quarterly report (10-Q) · SEC EDGAR
- 2026-05-07 filing 8-K items 2.02,9.01 · SEC EDGAR
125 earlier entries
- 2026-04-28 filing Proxy statement
- 2026-03-30 filing 8-K items 8.01
- 2026-03-25 filing SCHEDULE 13D/A
- 2026-03-23 filing Annual report (10-K)
- 2026-03-19 filing 8-K items 2.02,9.01
- 2026-03-16 filing 144
- 2026-03-03 filing 8-K items 2.02,2.05,7.01,9.01
- 2026-01-12 filing 8-K items 7.01,9.01
- 2025-12-08 filing 8-K items 8.01,9.01
- 2025-12-03 filing 144
- 2025-11-26 filing 144
- 2025-11-12 filing Quarterly report (10-Q)
- 2025-11-12 filing 144
- 2025-11-10 filing 8-K items 2.02,9.01
- 2025-08-25 filing 8-K items 8.01,9.01
- 2025-08-20 filing 8-K items 8.01
- 2025-08-13 filing Quarterly report (10-Q)
- 2025-08-12 filing 8-K items 2.02,9.01
- 2025-07-14 filing 144
- 2025-06-26 filing 8-K items 8.01,9.01
- 2025-06-06 filing 8-K items 8.01
- 2025-06-02 filing 144
- 2025-06-02 filing 8-K items 1.01,2.01,7.01,9.01
- 2025-05-20 filing 8-K items 5.07
- 2025-05-12 filing Quarterly report (10-Q)
- 2025-05-08 filing 8-K items 2.02,9.01
- 2025-04-10 filing Proxy statement
- 2025-03-07 filing Annual report (10-K)
- 2025-02-26 filing 8-K items 2.02,9.01
- 2025-01-21 filing 144
- 2024-11-14 filing Quarterly report (10-Q)
- 2024-11-12 filing 8-K items 2.02,9.01
- 2024-09-23 filing 8-K items 8.01
- 2024-09-10 filing 8-K items 7.01,9.01
- 2024-08-08 filing Quarterly report (10-Q)
- 2024-08-05 filing 8-K items 2.02,9.01
- 2024-05-15 filing Quarterly report (10-Q)
- 2024-05-13 filing 8-K items 2.02,9.01
- 2024-05-09 filing 8-K items 5.07
- 2024-04-05 filing Proxy statement
- 2024-03-05 filing SC 13D/A
- 2024-03-01 filing Annual report (10-K)
- 2024-02-28 filing 8-K items 8.01
- 2024-02-26 filing 8-K items 2.02,9.01
- 2024-01-16 filing 8-K items 8.01
- 2024-01-05 filing 8-K items 8.01,9.01
- 2023-12-28 filing 8-K items 8.01
- 2023-12-21 filing DEFA14A
- 2023-12-21 officer change 8-K items 1.01,5.02,7.01,9.01
- 2023-11-14 filing 144
- 2023-11-09 filing Quarterly report (10-Q)
- 2023-11-07 officer change 8-K items 2.02,5.02,9.01
- 2023-10-30 filing 8-K items 8.01
- 2023-10-16 filing 144
- 2023-09-14 filing 144
- 2023-09-12 filing 8-K items 7.01,9.01
- 2023-08-14 filing SC 13D/A
- 2023-08-11 filing 144
- 2023-08-09 filing Quarterly report (10-Q)
- 2023-08-07 filing 8-K items 2.02,9.01
- 2023-07-14 filing 144
- 2023-06-14 filing 144
- 2023-06-09 filing 8-K items 1.02
- 2023-06-08 filing 144
- 2023-05-18 filing 10-Q/A
- 2023-05-15 filing 144
- 2023-05-10 filing Quarterly report (10-Q)
- 2023-05-08 filing 8-K items 2.02,9.01
- 2023-05-03 officer change 8-K items 3.03,5.02,5.03,5.07,9.01
- 2023-04-17 filing 8-K items 7.01,9.01
- 2023-04-14 filing 144
- 2023-04-12 filing SC 13D
- 2023-04-11 filing DEFA14A
- 2023-04-11 filing DEFA14A
- 2023-04-11 officer change 8-K items 5.02,8.01
- 2023-03-28 filing Proxy statement
- 2023-03-17 filing PRE 14A
- 2023-03-13 filing 8-K items 7.01
- 2023-03-01 filing Annual report (10-K)
- 2023-03-01 officer change 8-K/A items 5.02
- 2023-02-28 filing DEFA14A
- 2023-02-28 filing DEFA14A
- 2023-02-28 filing 8-K items 8.01,9.01
- 2023-02-27 officer change 8-K items 2.02,5.02,9.01
- 2023-01-09 filing 8-K items 2.02,9.01
- 2022-12-12 officer change 8-K items 5.02
- 2022-11-22 filing SC TO-I/A
- 2022-11-18 filing SC TO-I/A
- 2022-11-14 filing SC TO-I/A
- 2022-11-14 filing 8-K/A items 9.01
- 2022-11-09 filing SC TO-I/A
- 2022-11-09 filing Quarterly report (10-Q)
- 2022-11-07 filing SC TO-I/A
- 2022-11-07 filing 8-K items 2.02,9.01
- 2022-11-03 filing 8-K items 7.01,9.01
- 2022-10-06 filing CORRESP
- 2022-09-29 filing UPLOAD
- 2022-09-28 filing SC TO-I
- 2022-09-20 filing SC 13D/A
- 2022-09-20 filing 8-K items 8.01
- 2022-09-19 filing 8-K items 1.01
- 2022-09-19 filing SC TO-C
- 2022-09-13 filing 8-K items 7.01,9.01
- 2022-08-25 filing 8-K items 8.01
- 2022-08-25 filing SC TO-I/A
- 2022-08-08 filing SC TO-I/A
- 2022-08-08 filing Quarterly report (10-Q)
- 2022-08-05 filing CORRESP
- 2022-08-05 filing SC TO-I/A
- 2022-08-04 filing 8-K items 2.02,9.01
- 2022-08-03 filing SC 13D/A
- 2022-08-01 filing UPLOAD
- 2022-07-26 filing SC TO-I
- 2022-07-20 filing 8-K items 2.01
- 2022-07-14 filing SC TO-C
- 2022-07-14 filing 8-K items 1.01,8.01,9.01
- 2022-07-13 filing SC TO-C
- 2022-07-13 filing 8-K items 8.01,9.01
- 2022-05-06 filing Quarterly report (10-Q)
- 2022-05-05 filing 8-K items 2.02,9.01
- 2022-04-28 filing 8-K items 5.07
- 2022-04-04 filing 8-K items 8.01,9.01
- 2022-03-25 filing Proxy statement
- 2022-03-04 filing S-8
- 2022-02-28 filing Annual report (10-K)
RENDERED FROM THIS PAGE
Relationship graph
Holders from 13F filings, subsidiaries from the GLEIF tree (by LEI), lobbying firms from LDA (possible match), agencies from USAspending, people from Forms 3/4/5, counsel from Exhibit 5.1, shared boards from Forms 3/4/5.
DATA MOTION // NEWEST FIRSTWhat changed
- 2026-10-05 (older) 15-12G filed
- 2026-09-24 (older) S-8 POS filed
- 2026-09-24 (older) S-8 POS filed
- 2026-09-24 (older) S-8 POS filed
- 2026-09-24 (older) S-8 POS filed
- 2026-09-24 (older) S-8 POS filed
- 2026-09-24 (older) S-8 POS filed
- 2026-09-24 (older) S-8 POS filed
Dot rule: red = within 7 days, amber = within 30 days, green = older. Measured against 2026-11-22; the colour is also written out in words.
COUNTS FROM THIS PAGERelationships at a glance
PRICE · FILINGS · POSTS · NEWSMarket & news
- Price
- No listing symbol is held for this company.
- Open in
Open in…
Insider trades
Official social
Each link opens the other site in a new tab, with this company filled in. That site shows its own data under its own terms; Seraphix stores none of it. Seraphix counts clicks per link, nothing about who clicked.
- Financials
- Filed figures: published SEC values, each linked to its filing.
- Official posts
- Links to posts from the company's and agencies' verified accounts: not connected yet.
- News
- Article links (headline, date, link): not connected yet.
EVERY RESOLVED IDENTIFIER1. Identity
0 possible matches held apart, matched by name only, not counted above.
| Identifier | Value | How it was resolved | Source |
|---|---|---|---|
| SEC CIK | 1583107 | id:sec-anchor: the SEC registrant record of this company | SEC EDGAR |
| CUSIP | G8807B106 | carried on the SEC-anchored record: listed in the identifiers of sx:sec:0001583107 | SEC EDGAR |
The company table did not answer, so only the identifiers carried on the SEC record are shown.
Next: reload in a minute, or open the record page.
AS FILED · EACH WITH ITS DATE AND FILING2. Filed figures
Key figures (annual filing)
| Figure | Value | Period or as of | Source | Basis | Retrieved | Report |
|---|---|---|---|---|---|---|
| Revenue (fiscal year ended 2025-12-31) | $107,464,000 | 2025-12-31 | 10-K, XBRL RevenueFromContractWithCustomerExcludingAssessedTax | as filed | 2026-11-22 03:14 UTC | Report an error |
| Net income (loss) (fiscal year ended 2025-12-31) | $105,895,000 | 2025-12-31 | 10-K, XBRL NetIncomeLoss | as filed | 2026-11-22 03:14 UTC | Report an error |
| Total assets (at 2025-12-31) | $485,570,000 | 2025-12-31 | 10-K, XBRL Assets | as filed | 2026-11-22 03:14 UTC | Report an error |
| Stockholders' equity (at 2025-12-31) | $296,723,000 | 2025-12-31 | 10-K, XBRL StockholdersEquity | as filed | 2026-11-22 03:14 UTC | Report an error |
| Cash and cash equivalents (at 2025-12-31) | $167,806,000 | 2025-12-31 | 10-K, XBRL CashAndCashEquivalentsAtCarryingValue | as filed | 2026-11-22 03:14 UTC | Report an error |
Company profile facts (SEC)
| Figure | Value | Period or as of | Source | Basis | Retrieved | Report |
|---|---|---|---|---|---|---|
| SEC entity type | operating | 2026-11-16 | SEC EDGAR company profile | as filed | 2026-11-22 03:14 UTC | Report an error |
| SIC industry | 2834 Pharmaceutical Preparations | 2026-11-16 | SEC EDGAR company profile | as filed | 2026-11-22 03:14 UTC | Report an error |
| State of incorporation | CA | 2026-11-16 | SEC EDGAR company profile | as filed | 2026-11-22 03:14 UTC | Report an error |
| Fiscal year end (MMDD) | 1231 | 2026-11-16 | SEC EDGAR company profile | as filed | 2026-11-22 03:14 UTC | Report an error |
| Business address | UGLAND HOUSE, SOUTH CHURCH STREET, GEORGE TOWN, GRAND CAYMAN, CA, KY1-1104 | 2026-11-16 | SEC EDGAR company profile | as filed | 2026-11-22 03:14 UTC | Report an error |
Other filed values
| Figure | Value | Period or as of | Source | Basis | Retrieved | Report |
|---|---|---|---|---|---|---|
| Operating cash flow (fiscal year ended 2025-12-31) | $238,541,000 | 2025-12-31 | 10-K, XBRL NetCashProvidedByUsedInOperatingActivities | as filed | 2026-11-22 03:14 UTC | Report an error |
| Capital expenditures (property, plant and equipment) (fiscal year ended 2025-12-31) | $42,000 | 2025-12-31 | 10-K, XBRL PaymentsToAcquireProductiveAssets | as filed | 2026-11-22 03:14 UTC | Report an error |
| Operating lease liabilities (at 2025-12-31) | $42,703,000 | 2025-12-31 | 10-K, XBRL OperatingLeaseLiability | as filed | 2026-11-22 03:14 UTC | Report an error |
Latest report: 10-Q for the period ended 2026-06-30, filed 2026-08-11 · accession 0001104659-26-093773
| Item | Value | Period | Form | Filed | Accession | Retrieved | Report |
|---|---|---|---|---|---|---|---|
| Revenue | $20,731,000 | 3 months ended 2026-06-30 | 10-Q | 2026-08-11 | 0001104659-26-093773 | 2026-11-22 03:14 UTC | Report an error |
| Net income (loss) | -$5,898,000 | 3 months ended 2026-06-30 | 10-Q | 2026-08-11 | 0001104659-26-093773 | 2026-11-22 03:14 UTC | Report an error |
| Cash and cash equivalents | $219,766,000 | at 2026-06-30 | 10-Q | 2026-08-11 | 0001104659-26-093773 | 2026-11-22 03:14 UTC | Report an error |
Values as filed in XBRL (SEC company facts); quarterly values are the filer's own 3-month figures, never derived.
No estimates: every value is as filed and links to the filing it came from.
Registration: the SEC filer status is under "Company profile facts (SEC)" above. SAM.gov registration status: not held yet.
NEWEST FIRST · EACH LINKS TO ITS FILING3. Registration and filing timeline
- 2026-10-05 Filing 15-12G filed
- 2026-09-24 Filing S-8 POS filed
- 2026-09-24 Filing S-8 POS filed
- 2026-09-24 Filing S-8 POS filed
- 2026-09-24 Filing S-8 POS filed
- 2026-09-24 Filing S-8 POS filed
- 2026-09-24 Filing S-8 POS filed
- 2026-09-24 Filing S-8 POS filed
- 2026-09-24 Filing S-8 POS filed
- 2026-09-24 Filing S-8 POS filed
- 2026-09-24 Filing S-8 POS filed
- 2026-09-23 Filing 25-NSE filed
- 2026-09-23 Filing 8-K filed: Item 1.01 material agreement; Item 2.01 acquisition or disposition; Item 3.01 delisting notice; Item 3.03 rights of holders modified; Item 5.01 change in control; Item 5.02 officer or director change; Item 5.03 charter or bylaw amendment; Item 8.01 other event; Item 9.01 exhibits
- 2026-09-18 Filing 8-K filed: Item 5.07 shareholder vote
- 2026-09-10 Filing 8-K filed: Item 8.01 other event
- 2026-08-25 Filing DEFA14A filed
- 2026-08-25 Filing 8-K filed: Item 8.01 other event; Item 9.01 exhibits
- 2026-08-21 Filing DEFM14A filed
- 2026-08-11 Filing PREM14A filed
- 2026-08-11 Filing 10-Q filed
- 2026-08-10 Filing 8-K filed: Item 2.02 results of operations; Item 9.01 exhibits
- 2026-06-29 Filing DEFA14A filed
- 2026-06-29 Filing 8-K filed: Item 1.01 material agreement; Item 7.01 Regulation FD disclosure; Item 8.01 other event; Item 9.01 exhibits
- 2026-06-23 Filing 8-K filed: Item 5.02 officer or director change
- 2026-06-12 Filing 8-K filed: Item 5.07 shareholder vote
8-K item text, as filed (excerpts)
- 2026-09-23 8-K Item 1.01, Entry into a Material Definitive Agreement
The information provided in the Introductory Note and Items 2.01 and 5.02 of this Current Report on Form 8-K is incorporated herein by reference. the 8-K · retrieved 2026-11-22 03:14 UTC - 2026-09-23 8-K Item 2.01, Completion of Acquisition or Disposition of Assets
The information provided in the Introductory Note of this Current Report on Form 8-K is incorporated herein by reference. Pursuant to the terms and conditions of the Merger Agreement, among other things: · Company Ordinary Shares: At the effective time of the Merger (the “Effective Time”), each ordinary share, par value $0.00001 per share, of the Company (“Ordinary Share”) issued and outstanding immediately prior to the Effective Time (other than Canceled Shares and Dissenting Shares) was canceled and converted into the right to receive (i) $17.00 in cash, without interest (the “Per Share Cash Consideration”), and (ii) one contingent value right, which represents the right to receive the… the 8-K · retrieved 2026-11-22 03:14 UTC - 2026-09-23 8-K Item 3.01, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
The information provided in Item 2.01 of this Current Report on Form 8-K is incorporated herein by reference. On September 23, 2026, the Company notified the Nasdaq Stock Market LLC (“Nasdaq”) of the Closing and requested that Nasdaq suspend trading of the Ordinary Shares as of the close of business on September 23, 2026 and file with the U.S. Securities and Exchange Commission (the “SEC”) a notification of removal from listing and registration on Form 25 to effect the delisting of the Ordinary Shares from Nasdaq and the deregistration of the Ordinary Shares pursuant to Section 12(b) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). The delisting of the Ordinary… the 8-K · retrieved 2026-11-22 03:14 UTC - 2026-09-23 8-K Item 3.03, Material Modification to Rights of Security Holders
The information provided in the Introductory Note and Items 2.01, 3.01, 5.01 and 5.03 of this Current Report on Form 8-K is incorporated herein by reference. At the Effective Time, each holder of shares of the Ordinary Shares issued and outstanding immediately prior to the Effective Time ceased to have any rights as a shareholder of the Company (other than the right of the holders of the Ordinary Shares to receive the Per Share Merger Consideration). the 8-K · retrieved 2026-11-22 03:14 UTC - 2026-09-23 8-K Item 5.01, Changes in Control of Registrant
The information provided in the Introductory Note and Items 2.01, 5.02 and 5.03 of this Current Report on Form 8-K is incorporated herein by reference. As a result of the completion of the Merger, a change in control of the Company occurred, and the Company became a wholly owned subsidiary of Parent. Parent obtained the funds necessary to finance the Merger through a combination of cash on hand and new debt financing. the 8-K · retrieved 2026-11-22 03:14 UTC - 2026-09-23 8-K Item 5.02, Departure of Directors or Certain Officers; Election of Directors; Appointment
of Certain Officers; Compensatory Arrangements of Certain Officers The information provided in the Introductory Note and Item 2.01 of this Current Report on Form 8-K is incorporated herein by reference. In connection with the completion of the Merger and as contemplated by the Merger Agreement, at the Effective Time, each of Rick E Winningham, Laurie Smaldone Alsup, Susannah Gray, Dean J. Mitchell, Donal O’Connor and Deepa R. Pakianathan resigned from the Company’s Board of Directors, and Mr. Winningham resigned as the Company’s Chief Executive Officer. These resignations were in connection with the Merger and not as a result of any disagreements between the Company and the resigning… the 8-K · retrieved 2026-11-22 03:14 UTC - 2026-09-23 8-K Item 8.01, Other Events
Contingent Value Rights Agreement On September 23, 2026, in connection with the Merger Agreement, Parent entered into a contingent value rights agreement (the “CVR Agreement”) with Computershare Inc., a Delaware corporation (“Computershare”), and its affiliate, Computershare Trust Company, N.A., a federally chartered trust company, acting jointly with Computershare, as Rights Agent (as defined in the CVR Agreement). Each CVR issued by Parent under the CVR Agreement represents a non-tradeable contractual contingent right to receive: · a pro rata share of 80% of the net proceeds received by Parent or its affiliates (including the Surviving Company), if any, from any license, divestiture or… the 8-K · retrieved 2026-11-22 03:14 UTC - 2026-09-18 8-K Item 5.07, Submission of Matters to a Vote of Security Holders
Theravance Biopharma, Inc. (“Theravance Biopharma” or the “Company”) held an extraordinary general meeting on September 18, 2026 (the “Extraordinary General Meeting”). At the Extraordinary General Meeting, the Company’s shareholders were asked to consider and vote on three proposals related to the Agreement and Plan of Merger, dated as of June 28, 2026 (as it may be amended, supplemented and restated from time to time, the “Merger Agreement”), by and among the Company, Zymeworks Inc., a Delaware corporation (“Parent”), and Zymeworks Merger Sub 1, an exempted company with limited liability incorporated under the laws of the Cayman Islands and a wholly owned subsidiary of Parent (“Merger… the 8-K · retrieved 2026-11-22 03:14 UTC - 2026-09-10 8-K Item 8.01, Other Events
As previously disclosed, on June 28, 2026, Theravance Biopharma, Inc., an exempted company with limited liability incorporated under the laws of the Cayman Islands (“Theravance Biopharma” or the “Company”), entered into an Agreement and Plan of Merger (the “Merger Agreement”) with Zymeworks Inc., a Delaware corporation (“Parent”), and Zymeworks Merger Sub 1, an exempted company with limited liability incorporated under the laws of the Cayman Islands and a wholly owned subsidiary of Parent (“Merger Sub”), providing for the merger of Merger Sub with and into the Company (the “Merger”), with the Company surviving the Merger as a wholly owned subsidiary of Parent. In connection with the Merger… the 8-K · retrieved 2026-11-22 03:14 UTC - 2026-08-25 8-K Item 8.01, Other Events
On August 25, 2026, Theravance Biopharma, Inc. (the “Company”) made available a presentation regarding the Phase 3 CYPRESS Study (0197) of ampreloxetine in patients with symptomatic neurogenic orthostatic hypotension (“nOH”) associated with multiple system atrophy (“MSA”), including post hoc analyses of data from the CYPRESS Study (0197) and information regarding the Company’s interactions with the U.S. Food and Drug Administration concerning the ampreloxetine clinical development program. A copy of the presentation is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information in this Current Report (including Exhibit 99.1) is being… the 8-K · retrieved 2026-11-22 03:14 UTC
Each excerpt is the first part of the item's own text, copied as filed and cut at a word; the filing has the rest.
AS FILED · LARGEST HOLDERS10. 13F institutional holders
| Rank | Holder (13F filer) | Value held | As of | Source | Retrieved | Report |
|---|---|---|---|---|---|---|
| 1 | Madison Avenue Partners, LP | $156,608,284 | 2026-06-30 | SEC 13F filing | 2026-11-22 03:14 UTC | Report an error |
| 2 | Weiss Asset Management LP | $126,770,020 | 2026-06-30 | SEC 13F filing | 2026-11-22 03:14 UTC | Report an error |
| 3 | BlackRock, Inc. | $77,562,279 | 2026-06-30 | SEC 13F filing | 2026-11-22 03:14 UTC | Report an error |
| 4 | Newtyn Management, LLC | $58,381,247 | 2026-06-30 | SEC 13F filing | 2026-11-22 03:14 UTC | Report an error |
| 5 | Irenic Capital Management LP | $46,936,116 | 2026-06-30 | SEC 13F filing | 2026-11-22 03:14 UTC | Report an error |
| 6 | VANGUARD CAPITAL MANAGEMENT LLC | $30,115,381 | 2026-06-30 | SEC 13F filing | 2026-11-22 03:14 UTC | Report an error |
| 7 | STATE STREET CORP | $22,585,928 | 2026-06-30 | SEC 13F filing | 2026-11-22 03:14 UTC | Report an error |
| 8 | TWO SIGMA INVESTMENTS, LP | $20,834,979 | 2026-06-30 | SEC 13F filing | 2026-11-22 03:14 UTC | Report an error |
| 9 | D. E. Shaw & Co., Inc. | $20,151,630 | 2026-06-30 | SEC 13F filing | 2026-11-22 03:14 UTC | Report an error |
| 10 | GEODE CAPITAL MANAGEMENT, LLC | $19,006,198 | 2026-06-30 | SEC 13F filing | 2026-11-22 03:14 UTC | Report an error |
13F as filed: the holder's own report of its position value at the quarter end.
WHAT THIS PAGE READ
Sources
JSON · MCP · API
API and agents
The same profile as JSON: GET /company/1583107.json. The MCP server and the records API return the same data: GET /v1/record/sx:sec:0001583107. Every source URL used is listed in the file.
Get the evidence file, alerts and the API with a free key. Everything on this page stays free to read.